Bergapten (5-methoxypsoralen)

Bergapten (5-methoxypsoralen) is a naturally occurring furanocoumarin found in citrus peels, parsley, and angelica root that functions as a photosensitizing agent. Its primary mechanism involves intercalating into DNA strands upon UVA activation, forming cyclobutane adducts that modulate cellular proliferation and immune responses in skin tissue.

Origin & History

Bergapten (5-methoxypsoralen) is a naturally occurring furanocoumarin found in essential oils from bergamot (Citrus bergamia) and other citrus species. It is typically extracted from bergamot oil or citrus fruits via solvent extraction or steam distillation of plant materials.

Historical & Cultural Context

While no specific traditional medicine systems are documented for bergapten use, it represents a modern application of natural psoralen derivatives from citrus plants for photochemotherapy. This builds upon historical psoralen traditions for treating skin disorders.

Health Benefits

• Effective for psoriasis treatment when combined with UVA light therapy, with clinical trials showing similar efficacy to 8-MOP with fewer side effects (moderate evidence)
• Demonstrates potential for vitiligo management in photochemotherapy applications (moderate evidence)
• Shows promise for mycosis fungoides treatment, with good tolerance reported in clinical use (preliminary evidence)
• May provide long-term benefits for atopic dermatitis when alternated with UVA1 therapy, with 12-month follow-up data showing superiority (moderate evidence)
• Exhibits anti-inflammatory properties by inhibiting mast cell degranulation and neutrophil infiltration in preclinical models (preliminary evidence)

How It Works

Bergapten absorbs UVA radiation (320–400 nm) and undergoes a photochemical reaction to form mono- and bi-functional covalent crosslinks with pyrimidine bases in DNA, inhibiting replication in hyperproliferating keratinocytes central to psoriasis pathology. It also modulates the expression of cytokines including IL-2 and TNF-α and suppresses T-lymphocyte activity by inhibiting calmodulin-dependent processes. Additionally, bergapten interacts with melanocyte-stimulating pathways, upregulating tyrosinase activity and promoting melanin synthesis relevant to vitiligo repigmentation.

Scientific Research

Clinical trials have primarily evaluated bergapten in photochemotherapy for skin disorders, with one randomized trial (n=169) comparing oral bergapten at 0.6-1.2 mg/kg to 8-MOP showing similar efficacy with minimal side effects. A trial in 40 atopic dermatitis patients demonstrated bergapten's superiority over UVA1 alone with 12-month follow-up benefits (PMID: 3279089 for related psoriasis photochemotherapy summary).

Clinical Summary

Randomized controlled trials comparing bergapten-PUVA (photochemotherapy) to 8-methoxypsoralen (8-MOP)-PUVA in psoriasis patients have demonstrated equivalent clearance rates—typically 70–85% improvement in PASI scores—while bergapten produced significantly lower rates of nausea and hepatotoxicity. A double-blind crossover study in approximately 50 psoriasis patients found that 5-MOP required modestly higher UVA doses for equivalent response but caused gastrointestinal side effects in fewer than 10% of subjects versus roughly 40% with 8-MOP. Evidence for vitiligo is moderate, with open-label and small controlled studies showing partial to complete repigmentation in 40–60% of patients after 6–12 months of topical or oral 5-MOP-PUVA therapy. Preliminary in vitro and animal data suggest antifungal properties against dermatophytes, though human clinical trials in this application remain limited.

Nutritional Profile

Bergapten (5-methoxypsoralen) is a naturally occurring furocoumarin compound, not a nutritional ingredient, and thus lacks conventional macronutrient or micronutrient content. It is a pure bioactive phytochemical with molecular formula C12H8O4 and molecular weight of 216.19 g/mol. Found naturally in plants at varying concentrations: bergamot oil contains approximately 0.3–1.8% bergapten by weight, celery (Apium graveolens) contains roughly 0.004–0.085 mg/g fresh weight, parsley contains approximately 0.003–0.02 mg/g, and fig leaves contain up to 0.12 mg/g. Grapefruit juice contains trace amounts (~0.001–0.01 mg/mL). As a furocoumarin, it contains no protein, fat, carbohydrates, fiber, vitamins, or minerals. Its biological activity is not nutritional but pharmacological, acting as a photosensitizing agent that intercalates with DNA upon UVA activation (320–400 nm). Bioavailability when ingested orally is moderate, with peak plasma concentrations reached within 1–2 hours; it undergoes hepatic first-pass metabolism via CYP450 enzymes (notably CYP3A4 inhibition). Lipophilic in nature (logP approximately 1.9), facilitating membrane permeability. Used therapeutically at doses of approximately 20–40 mg per session in photochemotherapy (PUVA) protocols, considerably lower than 8-methoxypsoralen.

Preparation & Dosage

Clinically studied oral doses for psoriasis photochemotherapy range from 0.6-1.2 mg/kg body weight, administered before UVA exposure. No standardized extract forms have been studied in humans. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

UVA light therapy, vitamin D3, omega-3 fatty acids, vitamin E, retinoic acid

Safety & Interactions

Bergapten carries a significant phototoxicity risk; sun or UVA exposure within 8–12 hours of oral ingestion or topical application can cause severe erythema, blistering, and hyperpigmentation. Long-term PUVA therapy using bergapten is associated with increased risk of squamous cell carcinoma and melanoma, necessitating periodic skin surveillance. It is a known inhibitor of CYP1A2 and CYP3A4 enzymes, potentially elevating plasma concentrations of substrates such as warfarin, caffeine, and certain statins; co-administration requires clinical monitoring. Bergapten is contraindicated in pregnancy due to mutagenic potential demonstrated in vitro, in patients with lupus erythematosus or xeroderma pigmentosum, and in individuals with a history of photosensitizing conditions.